Gala GLP-1

About Gala GLP-1

Gala GLP-1 is a 2023-founded telehealth provider offering compounded semaglutide and tirzepatide at prices between $199 and $299 per month. The company entered a crowded market but has built a modest following with competitive pricing and a straightforward enrollment process. Gala positions itself as an accessible option for patients who want GLP-1 therapy without the premium pricing charged by larger platforms.

The pricing structure is one of Gala’s more attractive features. With a 9 ceiling on monthly costs, the platform avoids the sticker shock that some competitors create with tiered plans reaching ,000 or more. Both semaglutide and tirzepatide are available as compounded formulations, giving patients the option to try either GLP-1 receptor agonist pathway. The onboarding process includes a medical intake and asynchronous provider review, which is standard for the category.

On Trustpilot, Gala GLP-1 holds a 4.4-star rating from 975+ reviews, a respectable score that suggests generally positive patient experiences. The review count is growing, and the rating has remained stable as volume increases, which is a positive signal. Common praise points include medication effectiveness and reasonable pricing. Complaints tend to center on shipping delays and communication gaps during the fulfillment process.

The company’s F rating with the BBB is a concern, though as noted throughout our reviews, BBB ratings in the telehealth GLP-1 space are frequently poor across the board. The F grade appears driven by complaint volume relative to the company’s size and unresolved disputes. Support is moderate, with Gala offering some level of ongoing patient communication but falling short of the comprehensive check-in protocols that top-tier providers maintain.

Gala GLP-1 is a growing provider still establishing its operational maturity. The fundamentals are reasonable: competitive pricing, both major GLP-1 compounds available, and solid Trustpilot feedback. The question is whether the company can scale its support infrastructure to match its patient growth. For now, it occupies a middle position in our rankings, neither a standout nor a concern, but a viable option for price-sensitive patients willing to accept some operational rough edges.

At a Glance